Litcius/Paper detail

What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?

Ian R. Reid

2022Expert Opinion on Drug Safety14 citationsDOI

Topics & Concepts

MedicineInternal medicineOsteoporosisIntensive care medicineBiomarkers in Disease MechanismsBone Metabolism and DiseasesCytokine Signaling Pathways and Interactions
What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab? | Litcius